Orthofix Medical Inc., a prominent global medical technology company, has announced the global commercial launch of its TrueLok Elevate Transverse Bone Transport $(TBT)$ System. This innovative device marks a significant milestone as the first commercially available system in the U.S. for the TBT procedure, providing a limb preservation treatment option for bony or soft tissue deformities, including diabetic ulcers. The launch follows FDA clearance and CE registration, with over 130 procedures already completed globally during a limited market release. This expansion is part of Orthofix's strategy to lead in limb reconstruction and address the growing diabetic wound market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.